RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States
Zhang, K. H., Winfree, K., Taipale, K. L., Muehlenbein, C. E., Panjic, E. H., & Graham, C. (2023). Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Value in Health, 26(6), S187. https://doi.org/10.1016/j.jval.2023.03.1013